ResMed
SAN DIEGO (February 13, 2017)—ResMed's global lead in remote patient monitoring kept growing in 2016, even as the industry itself continued to expand, according to the annual mHealth and Home Monitoring report released by independent technology analyst firm Berg Insight.
SAN DIEGO, Calif. and WINTER HAVEN, Fla. (January 24, 2017)—ResMed, BMC and 3B Medical, today announced they have agreed on a global settlement of all litigation between the parties. BMC and 3B will be permitted to sell their existing products in exchange for royalty payments to ResMed, and ResMed will make a one-time settlement payment to 3B to close the Florida litigation between the two parties. The settlement did not include an admission of liability or wrongdoing by any party.
SAN FRANCISCO (January 9, 2017)—ResMed announced today at the 35th annual J.P. Morgan Healthcare Conference that the U.S. Food and Drug Administration has cleared ResMed's AirMini, the world's smallest continuous positive airway pressure (CPAP) device.
ResMed's tiny yet fully-featured AirMini, to be launched later this year, is designed as a secondary CPAP, making it easier for people to continue their sleep apnea therapy while traveling.
SAN DIEGO (January 4, 2017)—ResMed today announced that it has achieved a new record in digital connected care: One billion nights of sleep data have been downloaded using ResMed's revolutionary remote patient monitoring platform, AirView.
SAN DIEGO (December 20, 2016)—ResMed announced that industry leader Carlos M. Nunez, MD, will become ResMed's chief medical officer, effective January 3, 2017.
Nunez most recently served as senior vice president of medical affairs for Becton, Dickinson and Company. He will be based in ResMed's San Diego headquarters and will report directly to CEO Mick Farrell and President/COO Rob Douglas.
ATLANTA (November 3, 2016)—ResMed announced two enhancements to AirView, a cloud-based remote patient monitoring platform that enables care teams to securely access therapy data from three million sleep apnea and respiratory care patients every day.
ATLANTA (November 3, 2016)—ResMed introduced this week at Medtrade 2016 the AirFit N20 nasal mask and AirFit F20 full face mask for positive airway pressure (PAP) treatment of sleep apnea. Loaded with innovations designed to improve mask fit, comfort and ease of use, the new-generation ResMed masks are the result of more than three years of research and development.
ATLANTA (November 3, 2016)—Several manufacturers earned awards at the recently concluded Medtrade.
The top three vote getters in the biannual Innovative HME Retail Product Awards, sponsored by HomeCare Magazine, were:
LOS ANGELES (October 25, 2016)—In a new research study being presented tomorrow at the CHEST 2016 annual meeting, ResMed will share evidence that people who use a self-management app when treating their sleep apnea with positive airway pressure (PAP) are significantly more likely to stick with their therapy.
SAN DIEGO, (October 18, 2016)—ResMed is teaming up with "The Dr. Oz Show" to launch a campaign to foster better public understanding of sleep health.
The campaign will kick off on "The Dr. Oz Show" airing Thursday, October 20.
SAN DIEGO (September 7, 2016)—ResMed welcomed positive results from a multicenter, randomized controlled trial known as HOT-HMV. The study was presented today during the 2016 European Respiratory Society International Congress in London.
SAN DIEGO (August 18, 2016)—myAir, ResMed’s program for CPAP users to track their own sleep apnea treatment, is now available in the United States as an iOS app in the Apple App Store.
How CPAP cross-platforms are transforming the sleep market for everyone in the care process
DENVER (June 23, 2016)—Remote monitoring and automated coaching from ResMed significantly improve the use of continuous positive airway pressure therapy for patients with obstructive sleep apnea, according to an independent Kaiser Permanente study presented last week at the SLEEP conference in Denver—the largest-ever randomized, controlled study on OSA in the United States.
ATLANTA (June 23, 2016)—Brightree, a provider of cloud-based software that improves clinical and business performance of post-acute care companies, announced new executive appointments to the company’s leadership team, which come as a result of its acquisition by ResMed earlier this year.
Matt Mellott will become the company’s new chief executive officer. In addition, Bobby Ghoshal will serve as Brightree’s new chief operating officer.
SAN FRANCISCO (May 16, 2016)—Patients using in-home life support and their clinicians are about to enjoy the latest in home health technology, remote patient monitoring, thanks to the world’s first cellular, cloud-connected in-home life support ventilators.
SAN DIEGO, Calif. (February 22, 2016)—ResMed, the world’s leading tech-driven medical device company and innovator in sleep-disordered breathing and respiratory care, today announced a definitive agreement to acquire privately held Brightree, a leader in business management and clinical software applications for the post-acute care industry. This acquisition adds to ResMed’s global leadership in connected health care solutions.
SAN DIEGO (February 3, 2016) A study showing significant, measurable efficiency gains when using the automated messaging capabilities of ResMed’s U-Sleep patient management solution was published this month in Sleep and Breathing, international journal of the science and practice of sleep medicine.
SAN DIEGO, Calif. (January 11, 2016)—ResMed today announced it has entered into a definitive agreement to acquire Inova Labs Inc., a privately held medical device company specializing in the development and commercialization of innovative oxygen therapy products. Oxygen therapy is the largest non-drug delivery medical device segment for the treatment of COPD.
One House Call Has Big Aging-In-Place Payoff
When it comes to helping seniors age in their own home, an in-home assessment from a physician or nurse practitioner goes a long way. (Tim Mullaney/Home Health Care News)
SAN DIEGO (November 5, 2015)—CareFusion, a BD company (NYSE: BDX), today announced its AirLife business line has signed an exclusive agreement with ResMed (NYSE: RMD) to distribute innovative nasal high flow interface products from the company.